The Ozempic Looked Real — Feds Say the Packaging, Labels and Even Needles Were Counterfeit

A box of Ozempic can look convincing enough to fool someone who has no reason to suspect the medication inside isn’t legitimate. Federal prosecutors now allege that two men went much further than putting a fake drug into a fake box: the counterfeit Ozempic included imitation packaging, package inserts, pen labels and even needles designed to make the products appear authentic. The recently announced federal charges stem from an alleged scheme that operated from at least July 2023 through April 2024 and involved products obtained from unauthorized sources in China. The allegations are particularly concerning because prosecutors say the counterfeit medication was distributed to people and businesses within the U.S. drug supply chain. For patients paying hundreds of dollars for medication, the case is a reminder that a bargain isn’t a bargain if you can’t verify what’s actually inside the package.

Federal Prosecutors Say the Counterfeits Came From China

The U.S. Department of Justice says Indian nationals Swapnadip Roy and Vicky Ramancha have been charged in connection with an alleged transnational counterfeit prescription-drug distribution operation. According to court documents, the men and their alleged co-conspirators obtained counterfeit Ozempic from unauthorized sources in China and sold it to co-conspirators and distributors in the United States at deeply discounted prices.

Prosecutors allege the activity occurred from at least July 2023 through April 2024, although an indictment contains allegations rather than proof of guilt. Roy was extradited from Italy and has pleaded not guilty, while Ramancha remained at large when federal officials announced the charges. Each defendant faces conspiracy, smuggling and counterfeit-drug charges, with prosecutors saying the maximum combined penalty could reach 71 years if they are convicted on all counts.

The Packaging Was Allegedly Part of the Deception

This wasn’t allegedly a case where someone simply stuck the Ozempic name on an obviously suspicious vial. The Food and Drug Administration says the products included counterfeit packaging, package inserts, pen labels and needles intended to convince downstream purchasers that they were receiving manufacturer-authorized Ozempic. That level of imitation matters because patients often depend on packaging, labeling and familiar-looking supplies when deciding whether a prescription appears legitimate. A convincing box therefore shouldn’t be treated as proof that the medicine or the components inside came through an authorized supply chain. The federal allegations show why identifying counterfeit Ozempic can be much harder than simply looking for misspelled words or cheap-looking packaging.

FDA Had Already Seized Thousands of Counterfeit Units

The new criminal case connects to a safety problem federal regulators began publicly warning about years earlier. In December 2023, the FDA warned consumers about counterfeit Ozempic after the agency seized thousands of units labeled as 1-milligram Ozempic from the legitimate U.S. drug supply chain. FDA specifically warned against products carrying lot number NAR0074 and serial number 430834149057, while testing confirmed counterfeit pen labels, cartons, patient and health-professional information and needles. Regulators said the sterility of those counterfeit needles couldn’t be confirmed, creating an increased risk of infection for patients using them. Prosecutors now allege the defendants and their co-conspirators continued distributing counterfeit products even after that seizure and FDA warning.

Counterfeit Medicine Creates Risks Beyond Getting Ripped Off

Losing money is bad enough, but paying for counterfeit Ozempic can create a much more serious problem when someone expects to receive a prescription medication. The FDA explains that counterfeit medicines can contain the wrong ingredients, too much or too little active ingredient, no active ingredient at all or potentially harmful substances. With the seized Ozempic products, regulators initially couldn’t confirm the identity, quality or safety of the drug and separately determined that the needles were counterfeit.

FDA reported five adverse events associated with the lot in its original warning, although none was serious and the reported symptoms were consistent with common adverse reactions to authentic Ozempic. Patients shouldn’t try to determine whether an unfamiliar medication is safe by injecting it and waiting to see whether it seems to work.

Why This Matters for Older Adults on Medicare

For older adults, the counterfeit warning arrives as GLP-1 drugs are becoming an increasingly visible part of Medicare coverage and retirement health-care spending. Ozempic is FDA-approved to treat type 2 diabetes, and Medicare Part D plans can cover GLP-1 medications when they’re prescribed for qualifying medical indications, although an individual beneficiary’s formulary and out-of-pocket costs can vary.

Medicare has also expanded access to certain other GLP-1 medications through its temporary Medicare GLP-1 Bridge, which began July 1, 2026, and gives eligible Part D beneficiaries access to covered weight-management drugs for a $50 monthly copay. Ozempic itself isn’t one of the weight-management drugs provided through that program, which is another reason seniors shouldn’t assume that an advertisement promising “Medicare Ozempic” or an unusually cheap online source represents legitimate coverage.

For retirees managing diabetes, cardiovascular risks, and multiple prescription expenses on a fixed income, verifying coverage through their Part D plan and filling prescriptions through legitimate pharmacies is safer than chasing a discount that could expose both their health and their savings to fraud.

A Deep Discount Can Be Especially Tempting on a Fixed Income

Prescription costs create exactly the kind of financial pressure counterfeiters can exploit, particularly when a retiree sees an opportunity to obtain an expensive medication for dramatically less than expected. Ozempic manufacturer Novo Nordisk currently lists the medication at roughly $1,050 per month, although what an insured patient actually pays can be far lower depending on Medicare or other insurance coverage, and the company has announced a lower $675 list price beginning in 2027.

Prosecutors specifically allege the counterfeit Ozempic in this case was sold to U.S. distributors at deeply discounted prices, making an unusually cheap offer something consumers should investigate rather than automatically celebrate. A patient who sends hundreds of dollars to an unauthorized seller could lose that money, still need to purchase legitimate medication, and potentially face additional medical expenses if an unsafe counterfeit causes a health problem. Before paying cash because an online offer appears cheaper than your pharmacy, Medicare beneficiaries should check what their Part D plan actually covers and ask their pharmacist or plan whether there is a legitimate lower-cost option.

Don’t Be Tempted

Prescription costs can make discounted medication particularly tempting, especially when insurance doesn’t cover a drug or leaves someone with substantial out-of-pocket costs. But prosecutors specifically allege the counterfeit Ozempic in this case was sold to U.S. distributors at deeply discounted prices, demonstrating why price alone can’t establish whether an offer is legitimate.

Someone who loses hundreds of dollars to counterfeit medication may then have to pay again for authentic treatment, while a health complication could create additional medical expenses. Before sending money to an unfamiliar online seller, patients should consider whether they’re dealing with a state-licensed pharmacy and whether the prescription process resembles what they’d expect from a legitimate medical provider. Trying to save money by stepping outside regulated channels can ultimately turn an expensive prescription into an even more expensive mistake.

Your Pharmacy Matters More Than a Convincing Box

Consumers shouldn’t assume they need to become counterfeit-drug investigators capable of spotting every tiny printing difference on a package. The FDA’s counterfeit-medicine guidance advises consumers to obtain medicines from state-licensed pharmacies and pay attention if a drug or its packaging suddenly looks different from what they normally receive. An unusual side effect or medication purchased from an online pharmacy can also be a reason to investigate further rather than assuming everything is fine. Patients who receive Ozempic through a legitimate pharmacy and notice unfamiliar packaging, labeling or supplies can ask the pharmacist to verify the product before using it. Where the medication came from provides a much stronger layer of protection than trusting a box simply because it looks professional.

Don’t Let the Search for Savings Override Safety

The price of prescription medication gives counterfeiters a powerful opening because people naturally look for less expensive ways to fill costly prescriptions, particularly when every recurring expense has to fit within a retirement budget. Yet this federal case shows how sophisticated a counterfeit can allegedly become when the box, instructions, pen label and even needles are designed to reinforce the same false impression.

Anyone who suspects they received counterfeit Ozempic should avoid using the questionable product and contact the pharmacy or health care professional involved rather than trying to authenticate it through appearance alone. Suspected counterfeit or tampered medicines can also be reported to the FDA, and adverse events can be submitted through the agency’s MedWatch program. Saving $100 or even several hundred dollars on a prescription isn’t a financial victory if the product isn’t authentic, so verifying the pharmacy and your legitimate Medicare coverage should come before chasing the lowest advertised price.

Would a deeply discounted price make you suspicious of an expensive prescription drug, or would professional-looking packaging be enough to reassure you?

What to Read Next

5 Prescription Pricing Tricks That Could Lower Your Ozempic Cost Without Insurance

Seniors Shocked by GLP-1 Prices: Does Medicare Cover Ozempic or Not?

Why Doctors Are Watching Ozempic’s Emerging Role in Post–Heart Attack Recovery

Amanda Blankenship

Amanda Blankenship is Chief Editor at District Media, Inc., leading content strategy, quality assurance, and editorial operations across high-traffic personal finance sites like SavingAdvice.com and CleverDude.com. A Wingate University graduate with a BA in Communications (Journalism focus), she brings over a decade of experience in digital publishing, writing, and team leadership in the personal finance space.